Bispecific antibody construct directed to MUC17 and CD3

US12258404B2 · kind B2 · utility

Assignees

• AMGEN INC. · US
• AMGEN RESEARCH (MUNICH) GMBH · DE

Inventors

• Tobias Raum · Munich, DE
• Tara Arvedson · Thousand Oaks, US
• Julie Bailis · Los Gatos, US
• Christoph Dahlhoff · Munich, DE
• Sandra Ross · Forest Park, US
• Irwin Chen · Moreno Valley, US
• Claudia Blümel · Munich, DE
• Elisabeth Nahrwold · Munich, DE
• Jochen Pendzialek · Munich, DE
• Joachim Wahl · Munich, DE

Key dates

• Filing date: Dec 31, 2018
• Grant date: Mar 25, 2025
• Expiry date: Sep 12, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/73
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides bispecific antibody constructs characterized by comprising a first domain binding to MUC17, a second domain binding to an extracellular epitope of the human and the Macaca CD3ε chain and optionally a third domain, which is a specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.